Dominique Remy-Renou to Lead European Sales and Support for Fluidigm.

SOUTH SAN FRANCISCO, Calif. -- Dominique Remy-Renou has joined Fluidigm Corporation, the leader in integrated fluidic circuits (IFCs) for life-science research, as the Vice President of European Sales and Support and General Manager of Fluidigm Europe BV. Ms. Remy-Renou has 20 years of life-science business experience, mostly at the European organization of Applied Biosystems (ABI). From 1997-2005, she was Country Manager for ABI France, one of the ABI's main businesses in Europe, and also held concurrent pan-European titles, including Manager of the Molecular Biology Business Unit and Senior Director of Marketing. In these combined roles, she gained valuable experience in sales, support, marketing, finance and administration.

"Retaining Dominique shows our commitment to building a global sales and marketing capability," said Fluidigm CEO Gajus Worthington. "Her background in molecular biology sales and her experience will certainly help us succeed in the European real-time qPCR market."

Early in her career Ms. Remy-Renou worked at Spectra Physics, France, and, subsequently, at Kratos, France. In 1987, she joined ABI as a Sales Engineer and over the next decade and a half was promoted to positions of increasing responsibility.

Ms. Remy-Renou's pan-European experience is expected to serve Fluidigm well as it ramps up sales of its BioMark[TM] system for real-time qPCR, which consists of instrumentation and specialized IFCs called dynamic arrays and digital arrays. IFCs have the potential to replace microwell plates in many applications because of their greater efficiency. Bioassays are assembled within a microscopic network of channels and valves, eliminating much of the liquid handling that characterizes the current microwell plate-based paradigm.

About Fluidigm

Fluidigm Corporation develops and distributes systems based on the unique properties of IFCs to precisely control fluids on a nanovolume scale. The Company's vision is to create and to lead a new industry in which IFCs bring unparalleled efficiencies to the life science and allied fields. Based in South San Francisco, California, the Company is privately held and backed by premier investors: Versant Ventures, Euclid SR Partners, InterWest Partners, Alloy Ventures, Lehman Brothers Healthcare Fund, Bio*One Capital, Bruce Burrows, Lilly BioVentures, the Invus Group, SightLine Partners, AllianceBernstein, Wasatch Advisors and its affiliate, Cross Creek Capital, and GE Equity.